ArticleBiology of sport2026
Accelerated biological aging and risk of sarcopenia: evidence from 29,000 Chinese adults.
Article in Biology of sport, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To construct biological age (BA)-based normative curves for muscle mass and strength and to determine whether biological age acceleration is associated with impaired muscle health and sarcopenia across adulthood. A total of 29,437 adults aged 20-80 years were analyzed from the China National Health Survey (2023-2024). BA was estimated using the Klemera-Doubal method (KDM) based on clinical biomarkers, and BA acceleration (BAacc) was defined as the residual of BA regressed on chronological age (CA). Appendicular skeletal muscle mass (ASM) and appendicular skeletal muscle mass index (ASMI) were assessed by bioelectrical impedance analysis, while handgrip strength (HGS) and relative handgrip strength (rHGS) were measured by dynamometer. Sex-specific BA-based percentile curves were generated using the Lambda-Mu-Sigma (LMS) method. Logistic regression models evaluated associations of BAacc with low muscle mass (LMM), low muscle strength (LMS), and sarcopenia. BA-based percentile curves revealed steady, sex-specific declines in ASM, ASMI, HGS, and rHGS across BA. Each one-year increase in BAacc was associated with significant reductions in ASMI (β = -0.0064 in men; -0.0041 in women) and rHGS (β = -0.0132 in men; -0.0064 in women) (all p < 0.0001). Accelerated BA (BAacc > 0) was linked to higher odds of LMM (73-77%), LMS (34-37%), and sarcopenia (68-78%), with dose-response relationships across quartiles. Associations were particularly pronounced in adults < 60 years, indicating that biological aging impacts muscle health earlier than the conventional threshold for old age. BA acceleration was strongly associated with impaired muscle mass, strength, and sarcopenia, with stronger effects observed in women and in younger adults. BA-based reference curves demonstrated clear, sex-specific declines in muscle health across adulthood, providing a novel reference framework for future sarcopenia research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.